Sponsored content brought to you by Most biopharma companies depend on a contract development and manufacturing organization (CDMO) for some steps—often all steps—in the production of material for clinical trials and manufacturing therapies. In late 2023, however, Gil Roth, president of the Pharma & Biopharma Outsourcing Association, wrote: “The last several years have been tumultuous for the CDMO sector.” Nonetheless, this sector continues to play a vital role in supplying customers with new and long-standing treatments, and many biopharma companies need to partner with an experienced and reliable CDMO.
Charles River Laboratories—founded in 1947 and headquartered in Wilmington, MA, just west of Boston—is a veteran contact research organization (CRO) and CDMO that supports clients from drug discovery and development through commercialization. In addition to conducting more than 1,000 studies in cell and gene therapies, including supporting the development of 20 of those approved by the FDA, the company constantly develops new tools and technologies to accelerate, improve, and scale the development of drug therapies. The development and manufacturing of cell or gene therapies requires safety and efficacy testing.
The latest in its portfolio, Charles River developed reference materials for adeno-associated viruses (AAV) and lentiviral vectors (LVV), including six AAV stereotypes and five LVV products. As Elizabeth Misleh, associate director, gene therapy research so.